Literature DB >> 25483697

Comparison of virulence between the Yersinia pestis Microtus 201, an avirulent strain to humans, and the vaccine strain EV in rhesus macaques, Macaca mulatta.

Guang Tian1, Zhizhen Qi, Yefeng Qiu, Xiaohong Wu, Qingwen Zhang, Xiaoyan Yang, Youquan Xin, Jian He, Yujing Bi, Qiong Wang, Jiyuan Zhou, Yanxiao Fan, Yazhou Zhou, Yongqiang Jiang, Ruifu Yang, Xiaoyi Wang.   

Abstract

Our previous study has demonstrated that Yersinia pestis Microtus 201 is a low virulent strain to the Chinese-origin rhesus macaques, Macaca mulatta, and can protect it against high dose of virulent Y. pestis challenge by subcutaneous route. To investigate whether the Y. pestis Microtus 201 can be used as a live attenuated vaccine candidate, in this study its intravenous virulence was determined and compared with the live attenuated vaccine strain EV in the Chinese-origin rhesus macaque model. The results showed that the Chinese-origin rhesus macaques can survive intravenous infection with approximately 10(9) CFU of the Y. pestis Microtus 201, but all the animals succumbed to 10(10) CFU of intravenous infection. By contrast, all the animals survive intravenous infection with 10(10) CFU of the vaccine EV. Post-mortem examination showed multiple areas of severe abscess in the lungs of the dead animals infected with 10(10) CFU of the Y. pestis Microtus 201, whereas histopathology observation, microbiological examination and immunohistochemistry staining showed that the Y. pestis Microtus 201 also invaded hearts, livers, spleens, kidneys and lymph nodes and caused different degrees of pathological changes in these organs. These results indicated that the Y. pestis Microtus 201 is indeed low virulent to monkeys, but it is more virulent than the vaccine EV when administered by intravenous route. The Y. pestis Microtus 201 mainly attack the lungs when administered by intravenous infection, which may be the leading cause of animal death.

Entities:  

Keywords:  CFU, colony-forming units; HE, haematoxylin and eosin; i.n.,intranasal; i.v., intravenous; live attenuated vaccine; plague; protection; rhesus macaques; s.c., subcutaneous; yersinia pestis

Mesh:

Substances:

Year:  2014        PMID: 25483697      PMCID: PMC4514055          DOI: 10.4161/hv.35119

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

1.  Human plague in 2002 and 2003.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2004-08-13

2.  Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.

Authors:  Alexander V Philipovskiy; Stephen T Smiley
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

3.  A new improved sub-unit vaccine for plague: the basis of protection.

Authors:  E D Williamson; S M Eley; K F Griffin; M Green; P Russell; S E Leary; P C Oyston; T Easterbrook; K M Reddin; A Robinson
Journal:  FEMS Immunol Med Microbiol       Date:  1995-12

Review 4.  Yersinia pestis--etiologic agent of plague.

Authors:  R D Perry; J D Fetherston
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

5.  Cell-mediated protection against pulmonary Yersinia pestis infection.

Authors:  Michelle A Parent; Kiera N Berggren; Lawrence W Kummer; Lindsey B Wilhelm; Frank M Szaba; Isis K Mullarky; Stephen T Smiley
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  In vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae.

Authors:  T Une; R R Brubaker
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

7.  A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model.

Authors:  P Russell; S M Eley; S E Hibbs; R J Manchee; A J Stagg; R W Titball
Journal:  Vaccine       Date:  1995-11       Impact factor: 3.641

Review 8.  Immune defense against pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

9.  Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans.

Authors:  Yajun Song; Zongzhong Tong; Jin Wang; Li Wang; Zhaobiao Guo; Yanpin Han; Jianguo Zhang; Decui Pei; Dongsheng Zhou; Haiou Qin; Xin Pang; Yujun Han; Junhui Zhai; Min Li; Baizhong Cui; Zhizhen Qi; Lixia Jin; Ruixia Dai; Feng Chen; Shengting Li; Chen Ye; Zongmin Du; Wei Lin; Jun Wang; Jun Yu; Huanming Yang; Jian Wang; Peitang Huang; Ruifu Yang
Journal:  DNA Res       Date:  2004-06-30       Impact factor: 4.458

10.  Multiple antimicrobial resistance in plague: an emerging public health risk.

Authors:  Timothy J Welch; W Florian Fricke; Patrick F McDermott; David G White; Marie-Laure Rosso; David A Rasko; Mark K Mammel; Mark Eppinger; M J Rosovitz; David Wagner; Lila Rahalison; J Eugene Leclerc; Jeffrey M Hinshaw; Luther E Lindler; Thomas A Cebula; Elisabeth Carniel; Jacques Ravel
Journal:  PLoS One       Date:  2007-03-21       Impact factor: 3.240

View more
  3 in total

Review 1.  Animal Models of Type III Secretion System-Mediated Pathogenesis.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Pathogens       Date:  2019-11-22

2.  Complete Protection Against Yersinia pestis in BALB/c Mouse Model Elicited by Immunization With Inhalable Formulations of rF1-V10 Fusion Protein via Aerosolized Intratracheal Inoculation.

Authors:  Wei Zhang; Xiaolin Song; Lina Zhai; Jianshu Guo; Xinying Zheng; Lili Zhang; Meng Lv; Lingfei Hu; Dongsheng Zhou; Xiaolu Xiong; Wenhui Yang
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

Review 3.  Plague vaccines: new developments in an ongoing search.

Authors:  Jason A Rosenzweig; Emily K Hendrix; Ashok K Chopra
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-18       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.